Patient Monitoring Market Size is Projected to Reach USD 112.47 Billion by 2033, Growing at a CAGR of 7.3%: Straits Research
The global patient monitoring market size was valued at USD 55.60 billion in 2024 and is projected to reach from USD 59.66 billion in 2025 to USD 112.47 billion by 2033, growing at a CAGR of 7.3% during the forecast period (2025-2033).
New York, United States, Jan. 27, 2025 (GLOBE NEWSWIRE) -- A set of instruments known as a patient monitoring system enables medical professionals to monitor a patient's health. These gadgets—remote physiologic monitoring—are routinely used for remote patient monitoring. Utilizing digital technology, they gather and track patient health data, transmit it electronically to healthcare specialists, and use it to aid in condition evaluation, diagnosis, and treatment. This technology alters how healthcare is delivered in the US by reducing costs and improving patient outcomes. Patient monitoring systems are easier to define in terms of their uses.
One well-known example of a patient monitoring system is electrocardiography (ECG), which records the heart's electrical activity. Hypertensive patients use monitoring tools to keep an eye on their blood pressure. People with diabetes utilize glucose monitoring equipment to assess blood glucose levels and prevent potentially dangerous consequences. Patients with chronic obstructive pulmonary disease (COPD), asthma, and other respiratory conditions also require monitoring equipment.
Download Free Sample Report PDF @ https://straitsresearch.com/report/patient-monitoring-market/request-sample
Market Dynamics
Growing Adoption of Remote Patient Monitoring Drives the Global Market
Recent years have seen a significant increase in the usage of patient monitoring devices for continuous vital sign monitoring and analysis, particularly during the COVID-19 outbreak. Patient monitoring systems enable medical personnel to monitor patients' health remotely or at home. Healthcare can become more digitalized to lower costs and boost revenue for medical practices. Additionally, remote monitoring equipment that provided medical treatment in a comfortable setting and permitted remote monitoring from patients' homes was helpful for non-COVID-19 patients who needed chronic care. This increased the number of beds and other important clinical resources available in hospitals and other healthcare facilities for patients who required immediate on-site care.
Due to stringent government regulations and favorable laws for patient monitoring equipment, it is anticipated that many organizations will be motivated to develop novel pharmaceuticals for treating chronic diseases like cardiovascular and respiratory diseases, cancers, diabetes, and chronic respiratory diseases. The widespread use of patient monitoring tools in clinical research trials and the convenience of monitoring is made possible by the market penetration of these tools, which hastens the development of novel medications. The increased prevalence of chronic diseases directly impacts the utilization of ICUs. Due to the benefits offered by patient monitoring devices, such as shorter hospital stays, fewer adverse effects, and speedier recovery times, the market is predicted to grow profitably.
Rising Demand in Non-Hospital Creates Tremendous Opportunities
The sustainability of the current healthcare system is a serious worry for governments worldwide. Due to escalating healthcare expenditures, particularly in hospital settings, the focus has recently switched to alternative treatment modalities, including home healthcare. In addition, the frequency of hospital readmissions has dramatically decreased since the introduction of remote and home monitoring technology. There is consequently a growing demand for effective home medical devices, such as fetal and neonatal monitors, ECG recorders, temperature monitors, pulse oximeters, and event monitors.
Regional Analysis
North America is the most significant patient monitoring market shareholder and is estimated to exhibit a CAGR of 8.1% over the forecast period. 42.7% of the market for patient monitoring devices was in North America. This results from several things: its well-established healthcare infrastructure, high healthcare spending, monopolistic market participants, and the rapid adoption of cutting-edge technologies. North America has the most developed medical equipment market worldwide. The market is anticipated to be driven by the quick adoption of patient monitoring and homecare devices for routine, continuous, and long-term patient monitoring and reducing the number of hospital visits during the projected period.
Additionally, favorable payment terms are expected to accelerate market expansion. Additional factors anticipated to drive market expansion include the rise in accidents, sports injuries, and health problems associated with lifestyle. Increased emergency care needs and increased usage of mobile surgery centers are expected to drive the market during the forecasted period.
Europe is anticipated to exhibit a CAGR of 8.4% over the forecast period. Europe accounted for 25.1% of the global market for patient monitoring devices in 2020. Europe's market includes countries including Germany, France, Italy, Spain, and the United Kingdom. The increasing demand for patient monitoring devices and central data management systems for accurate information and medical services is expected to boost the market. Market expansion is fueled by the prevalence of diseases and the growing older population. In 2020, more than one-fifth of people in Europe were over 65.
In Europe, the leading cause of illness and mortality is chronic disease. The requirement for patient monitoring devices has increased due to the number of patients admitted to healthcare facilities. The COVID-19 pandemic has increased the usage of patient monitoring devices and remote monitoring to assess and analyze vital signs in healthcare settings. To obtain more exact and accurate results economically, advanced patient monitoring devices are constantly being developed and presented by various market participants. As a result, the market for patient monitoring devices is anticipated to grow during the period in question.
Ask for Customization @ https://straitsresearch.com/report/patient-monitoring-market/request-sample
Key Highlights
The global patient monitoring market size was valued at USD 55.60 billion in 2024 and is projected to reach from USD 59.66 billion in 2025 to USD 112.47 billion by 2033, growing at a CAGR of 7.3% during the forecast period (2025-2033).
Based on the product, the global patient monitoring market is bifurcated into blood glucose monitoring systems, cardiac monitoring devices, multiparameter monitoring devices, respiratory monitoring devices, temperature monitoring devices, hemodynamic/pressure monitoring devices, fetal neonatal monitoring devices, neuromonitoring devices, weight monitoring devices, other. The blood glucose segment dominates the global market and is projected to exhibit a CAGR of 9.1% over the forecast period.
Based on end-users, the global patient monitoring market is divided into Hospitals, Ambulatory Surgery Centers, Home Care Settings, and Others. The hospital segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 8.2% over the forecast period.
North America is the most significant global patient monitoring market shareholder and is estimated to exhibit a CAGR of 8.1% over the forecast period.
Competitive Players
Abbott
Boston Scientific
Medtronic
Philips
Nihon Kohden Health Anywhere Inc.
Koninklijke Philips N.V.
G.E. Healthcare
MASIMO CORPORATION
Smiths Medical
Bosch
Biotronik
Intel
Welch Allyn
Recent Developments
In June 2023, With the introduction of its Generation (Gen) 1 device, medical diagnostic company Know Labs provides the first non-invasive glucose monitor. The Generation (Gen) 1 gadget prototype uses radio waves and machine learning algorithms to measure blood sugar levels through the skin.
In May 2023, Royal Philips, a global leader in health technology, and Masimo, a global medical technology company, announced FDA clearance for SedLine® Brain Function Monitoring, Regional Oximetry (O3®), and CO2 measurements in Philips Patient Monitors – IntelliVue MX750 and MX850. The latest extension will let clinicians make quick and informed judgments without additional monitoring equipment.
Segmentation
By Product
Blood Glucose Monitoring Systems
Cardiac Monitoring Devices
Multiparameter Monitoring Devices
Respiratory Monitoring Devices
Temperature Monitoring Devices
Hemodynamic/Pressure Monitoring Devices
Fetal and Neonatal Monitoring Devices
Neuromonitoring Devices
Weight Monitoring Devices
By End-User
Hospitals
Ambulatory Surgery Centers
Home Care Settings
By Region
North America
Europe
Asia-Pacific
Latin America
The Middle East and Africa
Get Detailed Market Segmentation @ https://straitsresearch.com/report/patient-monitoring-market/segmentation
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
Phone: +1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
COR Q1 Earnings Call: Specialty Expansion, RCA Impact, and International Softness Highlight Results
Healthcare distributor Cencora (NYSE:COR) met Wall Street's revenue expectations in Q1 CY2025, with sales up 10.3% year on year to $75.45 billion. Its non-GAAP profit of $4.42 per share was 7.9% above analysts' consensus estimates. Is now the time to buy COR? Find out in our full research report (it's free). Revenue: $75.45 billion vs analyst estimates of $75.7 billion (10.3% year-on-year growth, in line) Adjusted EPS: $4.42 vs analyst estimates of $4.10 (7.9% beat) Adjusted EBITDA: $1.32 billion vs analyst estimates of $1.22 billion (1.7% margin, 7.6% beat) Operating Margin: 1.4%, in line with the same quarter last year Market Capitalization: $55.09 billion Cencora's first quarter results were shaped by broad-based strength in its U.S. Healthcare Solutions segment, with management attributing growth to rising demand for specialty medications and higher utilization across health systems and specialty physician practices. CEO Bob Mauch highlighted the company's investments in end-to-end pharmaceutical services and deepening partnerships with providers as pivotal to this performance. The recent integration of Retina Consultants of America (RCA) was cited as a key contributor to gross profit margin expansion, with CFO Jim Cleary noting, 'RCA does add meaningfully to gross profit margin and operating margin… it is a higher-margin business than our core distribution business.' Management also pointed to ongoing productivity initiatives and a smaller-than-expected COVID-19 headwind as supporting factors. Looking ahead, Cencora's outlook is informed by its positioning in specialty pharmaceuticals, expectations for continued growth in the U.S. market, and ongoing integration of recent acquisitions. Management anticipates slower revenue growth in the second half of the year, citing tougher comparisons for GLP-1 products and biosimilar competition in mail-order channels. CFO Jim Cleary explained, 'We anticipate our growth will be at the bottom end of the respective ranges,' reflecting these headwinds but also suggesting potential margin benefits from product mix shifts. The company remains focused on expanding value-added services, strengthening specialty offerings across sites of care, and leveraging its data-driven insights to support both biopharma partners and healthcare providers. Management cited several operational and strategic developments as primary drivers of both quarterly results and the company's evolving competitive positioning. Specialty segment momentum: The company's specialty business, including physician practices and health systems, drove broad-based growth, supported by continued investments in services and wraparound offerings such as group purchasing organizations (GPOs) and management service organizations (MSOs). RCA integration impact: The acquisition of Retina Consultants of America contributed to margin expansion due to its higher profitability profile compared to Cencora's core distribution operations. The accounting treatment of RCA's minority interest also resulted in a higher-than-expected EPS contribution. GLP-1 product dynamics: GLP-1 (glucagon-like peptide-1) medications remained a significant revenue driver, though management noted a sequential decline from the prior quarter and minimal profit contribution. The company expects GLP-1 growth rates to moderate in upcoming quarters. International market softness: The International Healthcare Solutions segment experienced subdued demand, particularly in global specialty logistics and consulting related to clinical trials. Management described this as a market-wide issue and adjusted guidance downward to reflect slow recovery in these areas. Broad-based provider growth: Cencora reported growth across its specialty provider verticals, including oncology and retina, with management emphasizing robust positioning across community practices and health systems rather than concentration in any single sub-segment. Cencora's forward outlook is shaped by shifting specialty drug dynamics, international market uncertainty, and continued strategic investments in higher-margin services. Specialty and biosimilar expansion: Management expects specialty pharmaceuticals and biosimilars to remain key growth drivers, with continued investment in value-added services for both biopharma manufacturers and provider partners. The company's MSO and GPO offerings are designed to deepen relationships and capture a greater share of specialty market growth. International segment headwinds: The company anticipates ongoing weakness in its International Healthcare Solutions segment due to soft clinical trial activity and slower-than-expected recovery in global specialty logistics. Management revised down operating income expectations for this segment, citing industry-wide delays in clinical trial starts and subdued demand for consulting services. Product mix and margin effects: Shifts toward higher-margin specialty products and reduced contribution from lower-margin high-priced mail-order products are expected to benefit consolidated operating margins, partially offsetting slower top-line growth. Management noted that these mix effects will likely drive operating income growth above revenue growth, especially in the U.S. segment. Looking forward, the StockStory team will monitor (1) U.S. specialty drug utilization trends and the pace of biosimilar adoption, (2) the trajectory of international clinical trial activity and any signs of a rebound in specialty logistics, and (3) further integration milestones for RCA and the expansion of high-margin MSO services. The evolution of tariff policy and its potential effects on pharmaceutical supply chains will also be an important area for scrutiny. Cencora currently trades at a forward P/E ratio of 17.6×. At this valuation, is it a buy or sell post earnings? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study
(Reuters) -Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune responses in some patients tested in a late-stage study, the company said on Wednesday.


Associated Press
an hour ago
- Associated Press
Conavi Medical to Present at the Life Sciences Virtual Investor Forum June 12th
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ('Conavi Medical' or the 'Company'), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025 DATE: June 12th TIME: 2:00 PM ET LINK: REGISTER HERE This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at . Recent Company Highlights Upsized $20 million CAD financing led by U.S. institutional investors is expected to support finalizing product development of the next-generation Novasight Hybrid system, submit for regulatory clearance and enable commercial launch New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight's unique value proposition U.S. FDA 510(k) submission remains on track for calendar Q3 2025 About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit . About Virtual Investor Conferences® Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the April 2025 public offering, Conavi's exposure to the U.S. investment community, the commercialization and development of the Novasight Hybrid System and the achievement and timeline of key milestones towards commercialization and development of the Novasight Hybrid System. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are 'forward-looking information or statements'. Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'anticipate', 'believe', 'plan', 'expect', 'intend', 'estimate' 'anticipate' or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the 'Risk Factors' section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company's profile at ). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contacts: Conavi Medical Stefano Picone Chief Financial Officer [email protected] (416) 483-0100 Virtual Investor Conferences John M. Viglotti SVP Corporate Services, Investor Access OTC Markets Group (212) 220-2221 [email protected]